DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin

Information source: Lawson Health Research Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Neuropathic Pain

Intervention: Lidocaine (Drug); Diphenhydramine (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Lawson Health Research Institute

Official(s) and/or principal investigator(s):
Dwight Moulin, Dr., Principal Investigator, Affiliation: University of Western Ontario, Canada


Pain as a result of nerve injury (neuropathic pain) is a particularly severe form of chronic pain. Common examples of neuropathic pain are pain due to diabetes and shingles. There is good evidence that an intravenous infusion of lidocaine (local anesthetic) is useful for the

management of neuropathic pain in the short term - up to six hours.

Clinical Details

Official title: The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin

Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)

Primary outcome: Changes from Baseline Pain scores on the Visual Analog Scale at 6 weeks

Secondary outcome:

Hospital Anxiety and Depression Scale

Modified Brief Pain Inventory

Leeds Sleep Evaluation Questionnaire

Patient Global Satisfaction with Treatment and Impression of Change

Side Effects

Quality of Life Health Outcome Instrument

Detailed description: This study will examine the role of intravenous lidocaine in the relief of neuropathic pain over four weeks following infusion compared to a salt water infusion. If we can show that intravenous lidocaine provides sustained benefit for up to one month, this will be a major advance in the management of individuals suffering from neuropathic pain.


Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.


Inclusion Criteria:

- Chronic neuropathic pain of peripheral nerve origin as determined by the study

physician and a score of 4/10 or greater on the DN4 questionnaire.

- Moderate to severe pain as defined by screening average pain intensity of 5 or

greater on a 0-10 numerical rating scale.

- Neuropathic pain duration of at least 6 months.

Exclusion Criteria:

- Presence of clinically significant cardiac disease.

- Poorly controlled seizure disorder.

- Significant psychiatric disorder.

- History of allergy to lidocaine or any other amide local anesthetic

- History of allergy to diphenhydramine.

- Prior treatment with a local anesthetic infusion.

- Neuropathic pain due to cancer or complex regional pain syndrome

- Language barrier or cognitive impairment that would preclude understanding of the

study and filling out of questionnaires

- Lack of a driver to transport the patient to and from the pain clinic.

Locations and Contacts

St. Joseph's Health Care, London, Ontario N6A 4V2, Canada; Recruiting
Cathy Rohfritsch, RN, Phone: 519-646-6019
Dwight Moulin, Dr., Principal Investigator
Additional Information

Starting date: September 2011
Last updated: August 20, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017